During an Innovation Ignited webinar sponsored by Johnson & Johnson, experts talked about how precision medicine has helped advance the field of oncology and how those lessons can be applied to immunology. Advancements in precision medicine have helped oncologists know which drugs are most likely to help patients as their tumors advance and mutate. Read More
Chimeric antigen receptor (CAR) T-cell therapies (CAR T) have proven effective in several hematological cancers and are advancing across the pipelines of other types of tumors with limited efficacy, such as in the more complex environment of solid tumors. Read More
Shine Technologies LLC and WARF Therapeutics, a drug discovery program by the Wisconsin Alumni Research Foundation (WARF), have announced promising preclinical research results from collaborative efforts with the advanced radiotheranostics lab at the University of Wisconsin-Madison. Read More
Poseida Therapeutics Inc. has announced the nomination of a new development candidate under its collaboration with F. Hoffmann-La Roche Ltd., triggering a milestone payment from Roche to Poseida. Read More
Shenzhen Chipscreen Biosciences Co. Ltd. has submitted an IND application for CS-231295 tablets for the treatment of tumors, and the application has been accepted by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA). Read More
Paragon Therapeutics Inc. and Spyre Therapeutics Inc. jointly presented preclinical data for the novel extended half-life humanized anti-IL-23 monoclonal antibody (MAb), SPY-003, being developed for the treatment of inflammatory bowel disease (IBD). Read More
Shanghai Meiyue Biotech Development Co. Ltd. has synthesized spiro compounds acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration, glomerulonephritis, atypical hemolytic uremic syndrome, membranous nephropathy, myasthenia gravis, paroxysmal nocturnal hemoglobinuria, diabetic retinopathy and rheumatoid arthritis, among others. Read More
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has identified compounds acting as diacylglycerol kinase ζ (DGK-ζ, DGKZ) inhibitors reported to be useful for the treatment of cancer. Read More
Researchers from Chiesi Farmaceutici SpA published new clinical data for CHF-6467, a recombinant modified form of human nerve growth factor (NGF), being evaluated for the treatment of neonatal hypoxic-ischemic encephalopathy (HIE). Read More
Xuanzhu Pharma Co. Ltd. has divulged cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of castration-resistant prostate cancer. Read More
Prostate cancer accounts for 3.8% of total cancer-related deaths worldwide. The combination of docetaxel and androgen deprivation therapy is useful in the management of the disease, but unfortunately, prostate cancer cells become resistant to docetaxel over time. Read More
Among the mechanisms causing calcific aortic valve disease (CAVD) are mitochondrial dysfunction and immune cell infiltration, but it is not well understood just how they impact CAVD pathogenesis. Read More
Shaanxi Micot Technology Co. Ltd. has described theophylline derivatives acting as anticoagulant reversal agents reported to be useful for the treatment of hemorrhagic disorders. Read More
